Maintenance fees coming due

AstraZeneca AB

57 maintenance fees come due in the 12 months from Nov 14, 2026, the next on Dec 6, 2026. Unpaid by Jun 7, 2027, that one lapses early.

A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5 and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the six month grace period that follows.

Patent	Title	Holder	Status	Fee due	Lapses if unpaid	Expires	Confidence
US 11,667,615	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Fee due Dec 6, 2026 Lapses if unpaid Jun 7, 2027 Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Dec 6, 2026	Jun 7, 2027	Term ends Jan 21, 2035	Low confidence
US 9,050,258	Bilayer Tablet Formulations AstraZeneca AB In force Fee due Dec 9, 2026 Lapses if unpaid Jun 9, 2027 Term ends Nov 12, 2030 · High confidence	AstraZeneca AB	In force	Dec 9, 2026	Jun 9, 2027	Term ends Nov 12, 2030	High confidence
US 10,314,920	Therapeutic Dendrimers AstraZeneca AB In force Fee due Dec 11, 2026 Lapses if unpaid Jun 11, 2027 Term ends Feb 20, 2038 · High confidence	AstraZeneca AB	In force	Dec 11, 2026	Jun 11, 2027	Term ends Feb 20, 2038	High confidence
US 11,673,871	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Fee due Dec 13, 2026 Lapses if unpaid Jun 14, 2027 Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Dec 13, 2026	Jun 14, 2027	Term ends Jan 21, 2035	Low confidence
US 11,673,872	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Fee due Dec 13, 2026 Lapses if unpaid Jun 14, 2027 Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Dec 13, 2026	Jun 14, 2027	Term ends Jan 21, 2035	Low confidence
US 10,325,678	Systems and Methods for Facilitating Patient Self-Selection AstraZeneca UK Ltd. In force Fee due Dec 18, 2026 Lapses if unpaid Jun 21, 2027 Term ends Dec 20, 2036 · High confidence	AstraZeneca UK Ltd.	In force	Dec 18, 2026	Jun 21, 2027	Term ends Dec 20, 2036	High confidence
US 11,680,049	Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors AstraZeneca AB In force Fee due Dec 20, 2026 Lapses if unpaid Jun 21, 2027 Term ends Jan 21, 2035 · Low confidence	AstraZeneca AB	In force	Dec 20, 2026	Jun 21, 2027	Term ends Jan 21, 2035	Low confidence
US 11,685,953	Novel Biomarkers and Methods of Treating Cancer AstraZeneca AB In force Fee due Dec 27, 2026 Lapses if unpaid Jun 28, 2027 Term ends Aug 4, 2038 · High confidence	AstraZeneca AB	In force	Dec 27, 2026	Jun 28, 2027	Term ends Aug 4, 2038	High confidence
US 9,066,979	Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor AstraZeneca AB In force Fee due Dec 30, 2026 Lapses if unpaid Jun 30, 2027 Term ends Mar 5, 2034 · High confidence	AstraZeneca AB	In force	Dec 30, 2026	Jun 30, 2027	Term ends Mar 5, 2034	High confidence
US 10,336,725	Chemical Compounds AstraZeneca AB In force Fee due Jan 2, 2027 Lapses if unpaid Jul 2, 2027 Term ends Mar 17, 2035 · Medium confidence	AstraZeneca AB	In force	Jan 2, 2027	Jul 2, 2027	Term ends Mar 17, 2035	Medium confidence
47 more maintenance fees coming due in the 12 months from Nov 14, 2026 · Pro

10 of 57 patents shown. Soonest fee due date first, then patent number.

Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.

Upgrade to Pro

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.